Payment overview · 2025
General Payments
$117.50
7 reported records · 5 companies
Healthcare provider profile · identity verified
Nyan Win, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MANSFIELD, OH · NPI 1134187529
Verified facts
What the public records show
CMS Open Payments records show Nyan Win, MD received $117.50 in general payments during 2025 across 7 reported records.
ABBVIE INC. accounted for 46.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $54.99 | 46.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.20 | 18.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.57 | 14.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.74 | 12.5% | 1 | 2025 |
| VivaQuant Inc, dba Rhythm Express | Unresolved — no canonical attribution shown | $10.00 | 8.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $117.50 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $54.99 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| RHYTHM EXPRESS Normalized: rhythm express |
Device | VivaQuant Inc, dba Rhythm Express | $10.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 554 | 142 |
| Levothyroxine Sodium | Levothyroxine Sodium | 549 | 128 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 373 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 311 | 81 |
| Metformin Hcl | Metformin Hcl | 276 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 275 | 81 |
| Gabapentin | Gabapentin | 264 | 63 |
| Lisinopril | Lisinopril | 258 | 71 |
| Furosemide | Furosemide | 236 | 71 |
| Losartan Potassium | Losartan Potassium | 231 | 57 |
| Omeprazole | Omeprazole | 214 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 203 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 198 | 65 |
| Simvastatin | Simvastatin | 187 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 185 | 54 |
| Potassium Chloride | Potassium Chloride | 175 | 50 |
| Trazodone Hcl | Trazodone Hcl | 168 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 162 | 45 |
| Famotidine | Famotidine | 135 | 39 |
| Tramadol Hcl | Tramadol Hcl | 135 | 22 |
| Glimepiride | Glimepiride | 134 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 45 |
| Azithromycin | Azithromycin | 125 | 90 |
| Atenolol | Atenolol | 121 | 37 |
| Montelukast Sodium | Montelukast Sodium | 121 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 120 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 112 | 37 |
| Prednisone | Prednisone | 111 | 36 |
| Ezetimibe | Ezetimibe | 104 | 33 |
| Alprazolam | Alprazolam | 101 | 21 |
| Carvedilol | Carvedilol | 101 | 29 |
| Propranolol Hcl | Propranolol Hcl | 99 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 98 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 91 | 28 |
| Donepezil Hcl | Donepezil Hcl | 88 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 86 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 82 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 81 | 64 |
| Sertraline Hcl | Sertraline Hcl | 78 | 19 |
| Celecoxib | Celecoxib | 77 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 23 |
| Ibuprofen | Ibuprofen | 70 | 24 |
| Lorazepam | Lorazepam | 69 | 19 |
| Allopurinol | Allopurinol | 67 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 13 |
| Januvia | Sitagliptin Phosphate | 66 | 14 |
| Synthroid | Levothyroxine Sodium | 66 | 16 |
| Ozempic | Semaglutide | 65 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 63 | suppressed |
| Finasteride | Finasteride | 62 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 16 |
| Eliquis | Apixaban | 59 | 20 |
| Warfarin Sodium | Warfarin Sodium | 59 | 13 |
| Amoxicillin | Amoxicillin | 58 | 44 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | 19 |
| Spironolactone | Spironolactone | 53 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 16 |
| Memantine Hcl | Memantine Hcl | 51 | suppressed |
| Chlorthalidone | Chlorthalidone | 49 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 11 |
| Klor-Con M20 | Potassium Chloride | 47 | 15 |
| Lovastatin | Lovastatin | 47 | 16 |
| Mirtazapine | Mirtazapine | 47 | 13 |
| Nystatin | Nystatin | 46 | 26 |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 34 |
| Alendronate Sodium | Alendronate Sodium | 43 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 16 |
| Metformin Hcl Er | Metformin Hcl | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 30 |
| Ramipril | Ramipril | 39 | suppressed |
| Trulicity | Dulaglutide | 39 | 11 |
| Linzess | Linaclotide | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 34 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 32 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 14 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 29 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Metronidazole | Metronidazole | 27 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 16 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | 11 |
| Cephalexin | Cephalexin | 24 | 16 |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Premarin | Estrogens, Conjugated | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | 11 |
| Digoxin | Digoxin | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Dipyridamole | Dipyridamole | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Vasotec | Enalapril Maleate | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $117.50 · 7 records | ABBVIE INC. | REXULTI, RHYTHM EXPRESS, TRELEGY ELLIPTA, VRAYLAR, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error